NCT02090075View on ClinicalTrials.gov

Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque

PHASE4CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

December 27, 2016

Study Completion Date

April 5, 2017

Conditions
Atrial Fibrillation
Interventions
DRUG

apixaban

5 po or 2.5 po bid.

DRUG

warfarin

Trial Locations (1)

90502

Los Angeles Biomedical Research Institute, Torrance

All Listed Sponsors
lead

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

OTHER

NCT02090075 - Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque | Biotech Hunter | Biotech Hunter